Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

EU mid-market update: Risk appetite surges while market is laser-focused on Trump transition on Monday; Cool UK retail sales ...

Charting, Price Performance, News & Related Contracts.

DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy ...

EUR/USD shed another full percent as Euro fears simmer. European Manufacturing PMI missed the mark, implying steepening contraction expectations. ECB policies are expected to diverge steeply from ...

The euro fell to its weakest level versus the dollar in over two years and the pound slid to an eight-month low amid ongoing concerns about Europe’s economy. The common currency fell as much as ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other large-cap value stocks. The market outlook is as uncertain as it gets. On January 18 ...

In a report released today, Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price target of $91.70. The company’s shares ...

Investors in AstraZeneca plc (Symbol: AZN) saw new options begin trading today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AZN ...

AstraZeneca (NASDAQ:AZN) has changed several key management positions in its China business as the Anglo-Swedish drugmaker looks to boost its sales following the recent detention of its President ...